

**SUPPLEMENT DATED 24 SEPTEMBER 2018  
TO THE BASE PROSPECTUS DATED 13 APRIL 2018**

**SAMPO PLC**

*incorporated with limited liability in Finland*

**EUR 4,000,000,000 (increased from EUR 3,500,000,000)  
Euro Medium Term Note Programme**

This Supplement (the **Supplement**) to the Base Prospectus dated 13 April 2018 as supplemented by the first supplement dated 11 May 2018 (as so supplemented, the **Base Prospectus**) which comprises a base prospectus, constitutes a supplementary prospectus for the purposes of Section 87G of the Financial Services and Markets Act 2000 (the **FSMA**) and is prepared in connection with the Euro Medium Term Note Programme (the **Programme**) established by Sampo plc (the **Issuer**). Terms defined in the Base Prospectus have the same meaning when used in this Supplement.

This Supplement is supplemental to, and should be read in conjunction with, the Base Prospectus and any other supplements to the Base Prospectus issued by the Issuer.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer (which has taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

**Purpose of this Supplement**

The purpose of this Supplement is (a) to increase the Programme Size (as defined below), (b) to incorporate by reference the Issuer's "Interim Report Q2/2018" for the six month period ended 30 June 2018 (the **Q2 Interim Report**) and (c) to include a new Significant Change statement.

**Increase in the Programme Size**

Pursuant to the Dealer Agreement dated 13 April 2018 (as modified and/or supplemented and/or restated from time to time, the **Dealer Agreement**), the maximum aggregate principal amount of Notes issued by the Issuer under the Programme that may be outstanding at any one time (the **Programme Size**) is increased from the current Programme Size of EUR 3,500,000,000 to EUR 4,000,000,000 (or its equivalent in other currencies calculated as described in the Dealer Agreement). From the date of this Supplement, all references in the Base Prospectus to the Programme Size of EUR 3,500,000,000 shall be deemed to be references to the Programme Size of EUR 4,000,000,000. The Programme Size may be further increased from time to time in accordance with the Dealer Agreement.

The increase of the Programme Size from EUR 3,500,000,000 to EUR 4,000,000,000 has been duly authorised by a resolution of the Board of Directors of the Issuer passed on 12 September 2018.

**Q2 Interim Report for the six month period ended 30 June 2018**

On 8 August 2018 the Issuer published its Q2 Interim Report, which contains its unaudited interim financial statements as at and for the six month period ended 30 June 2018.

A copy of the Q2 Interim Report has been filed with the Financial Conduct Authority and, by virtue of this Supplement, the Q2 Interim Report is incorporated in, and forms part of, the Base Prospectus.

Copies of all documents incorporated by reference in the Base Prospectus may be inspected, free of charge, at Fabianinkatu 27, FI-00100 Helsinki, Finland and are available in electronic form at [www.sampo.com/investors](http://www.sampo.com/investors).

If documents which are incorporated by reference themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of this Supplement for the purposes of the Prospectus Directive (Directive 2003/71/EC) except where such information or other documents are specifically incorporated by reference or attached to this Supplement.

### **General Information**

Since 30 June 2018, there has been no significant change in the financial or trading position of the Issuer and its Subsidiaries.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any other statement in or incorporated by reference in the Base Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement, there has been no other significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus since the publication of the Base Prospectus.